selegiline has been researched along with Medulloblastoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baghy, K; Eckhardt, S; Ferdinandy, P; Garami, M; Harsing, LG; Hauser, P; Knoll, J; Mervai, Z; Miklya, I; Pocza, T; Schaff, Z; Schuler, D | 1 |
1 other study(ies) available for selegiline and Medulloblastoma
| Article | Year |
|---|---|
A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
Topics: Animals; Antineoplastic Agents; Benzofurans; Brain; Cell Line, Tumor; Dose-Response Relationship, Drug; Fibrosarcoma; Humans; Longevity; Male; Medulloblastoma; Monoamine Oxidase Inhibitors; Rats; Rats, Wistar; Selegiline | 2017 |